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METHODOLOGY Open Access
Expert panel process to optimise the
design of a randomised controlled trial
in chronic rhinosinusitis (the MACRO
programme)
Helen Blackshaw1*, Jane Vennik2 , Carl Philpott3,4, Mike Thomas2, Caroline Eyles2, James Carpenter6,
Caroline S. Clarke7, Steve Morris8, Anne Schilder1, Valerie Lund1, Paul Little4, Stephen Durham9, Spiros Denaxas5,
Elizabeth Williamson5, David Beard10, Jonathan Cook10, Steffi Le Conte10, Kim Airey1, Jim Boardman12 and
Claire Hopkins11
Abstract
Background: MACRO (Defining best Management for Adults with Chronic RhinOsinusitis) is an NIHR-funded
programme of work designed to establish best practice for adults with chronic rhinosinusitis (CRS). The 7-year
programme comprises three consecutive workstreams, designed to explore NHS care pathways through analysis of
primary and secondary data sources, and to undertake a randomised controlled trial to evaluate a longer-term
course of macrolide antibiotics and endoscopic sinus surgery for patients with CRS. A number of outstanding
elements still required clarification at the funding stage. This paper reports an expert panel review process designed
to agree and finalise the MACRO trial design, ensuring relevance to patients and clinicians whilst maximising trial
recruitment and retention.
Methods: An expert panel, consisting of the MACRO Programme Management Group, independent advisors, and
patient contributors, was convened to review current evidence and the mixed-method data collected as part of the
programme, and reach agreement on MACRO trial design. Specifically, agreement was sought for selection of
macrolide antibiotic, use of orally administered steroids, inclusion of CRS phenotypes (with/without nasal polyps),
and overall trial design.
Results: A 12-week course of clarithromycin was agreed as the main trial comparator due to its increasing use as a
first- and second-line treatment for patients with CRS, and the perceived need to establish its role in CRS
management. Orally administered steroids will be used as a rescue medication during the trial, rather than routinely
either pre or post trial randomisation, to limit any potential effects on surgical outcomes and better reflect current
UK prescribing habits. Both CRS phenotypes will be included in a single trial to ensure that the MACRO trial is both
pragmatic and generalisable to primary care. A modified, three-arm trial design was agreed after intense discussions
and further exploratory work. Inclusion criteria were amended to ensure that the patients recruited would be
considered eligible for the treatment offered in the trial due to having already received appropriate medical
therapy as deemed suitable by their ENT surgeon. A proposed 6-week run-in period prior to randomisation was
removed due to the new criteria prior to randomisation.
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Conclusion: The expert panel review process resulted in agreement on key elements and an optimal design for
the MACRO trial, considered most likely to be successful in terms of both recruitment potential and ability to
establish best management of patients with CRS.
Keywords: Expert panel, Mixed methods, Consensus, Decision-making, Chronic rhinosinusitis
Introduction
MACRO (Defining best Management for Adults with
Chronic RhinOsinusitis) is an National Institute for
Health Research (NIHR)-funded programme of work de-
signed to establish best practice for adults with chronic
rhinosinusitis (CRS) [1]. CRS is a chronic inflammatory
condition of the nose and paranasal sinuses, with symp-
toms such as nasal congestion, nasal discharge, facial
pain/pressure, and anosmia which significantly impact on
a patient’s quality of life [2, 3]. Prevalence rates of CRS
reach 10% in the UK adult population [4]. Whilst many
patients are managed in the community, there is signifi-
cant onward referral to specialist ear, nose, and throat
(ENT) services. This results in up to 120,000 outpatient
consultations and in excess of 40,000 surgical procedures
for CRS in England and Wales annually. There are, as yet,
no National Institute for Health and Care Excellence
(NICE) guidelines for managing patients with CRS. The
European Position Paper (EPOS) [5] provides recommen-
dations, but it is unclear how widely they are known about
or used in UK clinical practice. The MACRO programme
is a 7-year programme of work which sets out to help to
formulate new recommendations for CRS patient manage-
ment across primary and secondary care. The MACRO
programme has been designed by a multidisciplinary team
including ENT specialists, general practitioners (GPs),
health economists, statisticians, qualitative researchers,
and experienced clinical triallists from across the UK. It is
divided into three consecutive workstreams with the fol-
lowing aims and objectives:
Workstream 1: To explore current National Health
Service (NHS) care pathways for adults with CRS
through: (1) analysis of routine data from health records,
(2) cost analysis of care pathways, and (3) qualitative
analysis of stakeholder views of current management
Workstream 2: To evaluate the effectiveness of
endoscopic sinus surgery (ESS) and long-term anti-
biotic treatment for patients with CRS, including those
with (CRSwNP) and without (CRSsNP) nasal polyps
Workstream 3: To combine outcomes from the
workstreams 1 and 2 to define the best care pathways
for adults with CRS
National Institute for Health Research (NIHR)
programme grants are aimed at providing research for
the benefit of patients, public, and the NHS. There is an
emphasis on multidisciplinary approaches and collabor-
ation to ensure that the research is both relevant and ap-
plicable [1]. Within a programme of work there are
commonly decision or ‘stop-go’ points which need an-
swering before work continues. In the MACRO
programme, the NIHR funding panel identified three
key issues that required resolution prior to commencing
workstream 2. These included: (1) the commitment to
the use of clarithromycin as the trial comparator; (2) the
use of orally administered corticosteroids (OCS) pre or
post trial randomisation, and (3) possible differences in
the natural history, and hence management, of CRS with
and without nasal polyps. Additionally, two trial designs
were proposed by the research team to address the re-
search question regarding the effectiveness of long-term
antibiotics and ESS for patients with CRS. Both were
considered to be equally valid, but there were uncertain-
ties about how each design might be implemented in
practice, the acceptability to patients, and potential im-
plications for patient recruitment and retention. Design
1 consisted of a single-stage, three-arm trial (ESS vs
macrolide vs placebo) (Fig. 1), whilst Design 2 consisted
of a two-stage, two-comparison trial (stage 1: macrolide
vs placebo, followed by stage 2: ESS vs ongoing medical
management for symptomatic patients) (Fig. 2).
It was agreed with the NIHR programme panel
that the results of workstream 1 would be used to
determine the key elements of the final trial design,
using a multidisciplinary and collaborative approach.
This paper reports the process of convening an ex-
pert panel of researchers, methodologists, triallists,
and public contributors to review and integrate
current evidence with the mixed-method data col-
lected in workstream 1. The aim of this process was
to address and resolve the following outstanding trial
elements:
i. To justify and commit to the use of clarithromycin
in the MACRO trial
ii. To agree on the role of OCS both pre and post
randomisation to the MACRO trial
iii. To review treatment and management pathways for
CRSwNP and CRSsNP patients, and agree how best
to evaluate both phenotypes in the trial
iv. To agree on the final MACRO trial design.
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Methods
Study design
This is an expert panel review of current evidence and
mixed-method data to reach agreement on key elements
of the MACRO trial design, as part of a decision-making
process in an NIHR programme of work in CRS.
Expert panel
An expert panel was convened by the MACRO
programme manager (HB) on 12 July 2017 at the
Royal College of Surgeons, London. The panel in-
cluded: (1) members of the MACRO Programme
Management Group (PMG) (MACRO chief investiga-
tors, co-investigators across the specialist areas, the
programme manager and a patient contributor); (2)
researchers and operational teams involved in
workstreams 1 and 2; and (3) independent contribu-
tors including a professor of medicine, a qualitative
researcher and a patient and public contributor,
recruited through personal contact (clinician and re-
searcher) and through the Fifth Sense charity (pa-
tient). The role of the independent contributors was
to provide an impartial view to the review of the re-
search data and help the team to reach agreement.
Each independent contributor was asked to sign a
confidentiality agreement prior to the expert panel
meeting in light of the pre-publication research data.
Prior to the meeting, all panel members received an
information pack detailing the background and aims
of the MACRO programme, the purpose of the expert
panel meeting, and the role of invited independent
members. The meeting was chaired by Professor
Fig. 1 Single-stage, three-arm trial design
Fig. 2 Two-stage, two-comparison trial design
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Claire Hopkins, joint chief investigator of the
MACRO programme, and lasted for a total of 4 h.
Data collection
Quantitative data
Quantitative observational cohort data were obtained
from the Clinical Practice Research Datalink primary
care database, the Hospital Episode Statistics (HES) hos-
pital care database in England, and the Office for Na-
tional Statistics mortality dataset. Linked electronic
health records from these sources were examined
through the CALIBER platform. Access was granted fol-
lowing an Independent Scientific Advisory Committee
(ISAC) application (protocol number 16_200R). Primary
care data were extracted from the Clinical Practice Re-
search Datalink (CPRD) Gold (January 2017 version).
Hospital Episode Statistics data were obtained for
CPRD-linked patients, with coverage up to 29 February
2016. Office of National Statistics death data were ob-
tained for CPRD-linked patients, with coverage up to 8
March 2016. Patients with a diagnostic term of polyps in
the HES data for surgery provided a level of certainty of
phenotype diagnosis. However, recording of polyp status
in secondary care data is poor, and there are diagnostic
uncertainties in primary care due to limited specialist
equipment. The data are, therefore, presented as ‘polyps
present’ (requiring surgery) and ‘polyps unknown’ (likely
to include those with less severe polyps not requiring
surgery, together with those without polyps).
Qualitative data
Qualitative data were collected via semi-structured tele-
phone interviews with a purposeful sample of 12 GPs,
nine ENT specialists and 25 patients with CRS recruited
through primary and secondary care between January
and April 2017. Ethical approval was given by the Health
and Social Care Research Ethics Committee A on 22
September 2016 (16/NI/0197) and all participants gave
their informed consent prior to the interview. Healthcare
professionals were asked about their views of diagnosis
and management of CRS, knowledge and implementa-
tion of guidelines, and perceptions of the evidence base.
Patients were asked about their experiences of living
with CRS, and views of the different treatment options
available in primary and secondary care. All participants
were presented with the two trial designs (Figs. 1 and 2)
prior to the interview and asked their views and opin-
ions about the barriers and facilitators to each design,
with respect to treatment arms, timings of treatments,
recruitment of patients and retention in the trial. Further
details about recruitment and data collection are pub-
lished elsewhere [6].
Analysis
Qualitative and quantitative data were individually ana-
lysed in three separate analyses: health informatics (EW,
SD, JC), health economics (CC, SM), and qualitative (JV,
CE, MT). The methods and results of these individual
analyses are presented independently elsewhere [6]. The
expert panel convened in July 2017. Prior to the meet-
ing, panel members received information about the
MACRO programme, including details about the three
workstreams and research methods used in workstream
1. During the meeting, the joint chief investigators (CH
and CP) presented background to the MACRO
programme, the recent literature and outlined the spe-
cific aims and objectives of the panel meeting. The four
key aims were addressed in turn. In each case, a review
of the current evidence was presented (CH). The results
of the individual analyses were then presented: health in-
formatics, qualitative work, and health economics. The
data were then discussed and debated, with areas of
agreement, partial agreement, and disagreement identi-
fied. Each member had the opportunity to ask questions
and contribute to the discussions. Resolution for each key
point was summarised and proposed by the chair (CH)
and voted on with a ‘show of hands’ by the panel mem-
bers. All members’ responses carried equal weight, and
consensus was determined by majority view. Where pos-
sible, discussions continued until agreement was reached.
In the case where discussions did not lead to a majority
view, a post-panel meeting plan of action was agreed.
Results
Selecting the appropriate macrolide antibiotic
Current evidence
Macrolide antibiotics have been shown to have
anti-inflammatory and immunomodulatory properties,
reducing the pro-inflammatory cytokines critical in CRS
[7, 8]. International guidelines recommend the use of
low-dose, long-term macrolides in selected patients with
CRS but the evidence is weak, and also based on roxithro-
mycin which is not currently available in the UK [9, 10]. A
survey of 158 UK ENT surgeons (2013) [11] found that
92% prescribed antibiotics prior to ESS surgery, with 16%
prescribing 12 weeks’ macrolide treatment. The UK sino-
nasal audit [12] in 2000 found that 7% of CRSwNP and
18.9% of CRSsNP patients received low-dose, long-term
antibiotics prior to ESS.
Treatment duration has been evaluated in some
low-quality studies, but the evidence suggests that longer
courses of macrolide therapy are more effective than
shorter courses in patients with CRS [13, 14].
More recently, concerns have been raised about potential
cardiovascular risks from the use of full-dose, short-term
macrolides [15]. Macrolides may cause prolongation of the
QT interval which can lead to arrhythmia and myocardial
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infarction. However, the safety of lower doses for longer pe-
riods in such cases for CRS has yet to be investigated.
Health informatics
The health informatics analysis evaluated current trends
in antibiotic prescribing, including treatment duration and
safety. The analyses found that penicillins remain the
first-choice antibiotic for patients with a high likelihood of
CRS; however, a recent trend towards the increased use of
macrolides and tetracyclines (mainly doxycycline) was
found for patients with a definitive diagnosis of CRS.
The most common treatment duration for both macro-
lide and penicillin prescriptions for CRS was found to be
1 week. However, macrolides were likely to be prescribed
for a longer durations (over 8 weeks) than penicillins, par-
ticularly for those with a definitive CRS diagnosis.
Analysis of macrolide safety data found that there was
no statistically significant short- or long-term risk asso-
ciated with macrolide prescription compared to penicil-
lin for patients with CRS. A potential (non-significant)
short-term risk of myocardial infarction during the first
30 days following prescription was found with macrolide
antibiotics. However, no significant risks were particu-
larly associated with clarithromycin, and there was no
evidence of increased risk of cardiovascular events.
Qualitative findings
GPs described prescribing short courses of antibiotics in
primary care, with limited experience of long-term anti-
biotic use for patients with CRS. ENT surgeons com-
monly described the use of clarithromycin in patients
prior to sinus surgery; however, treatment durations
were often less than 8 weeks, and generally for CRSwNP
patients. Patients described the role of antibiotics as ap-
propriate to treat infections and were uncertain about
their use in CRS. Some expressed concerns about poten-
tial gastrointestinal side effects and antibiotic resistance,
especially with longer courses of treatment.
Expert panel review
The expert panel agreed that clarithromycin should be
selected as the macrolide of choice for the MACRO trial
due to its increasing use as a first- and second-line treat-
ment for patients with CRS, and the perceived need to
establish its role in CRS management. A 12-week course
of treatment was selected as the appropriate treatment
duration based on the evidence for effectiveness with
longer treatment durations and no associated increased
risk with longer treatment courses. To mitigate against
any potential problems associated with increased cardio-
vascular risk with macrolide treatment, the panel agreed
that patients with a prior history of ischaemic heart
disease and those aged over 65 years with diabetes will
be excluded from the MACRO trial. A baseline
electrocardiogram (ECG) will be added to the trial
screening process to identify and exclude those with
prolongation of the QT interval.
Role of orally administered corticosteroids (OCS)
Current evidence
Short courses of OCS are commonly used in treating pa-
tients with CRS, either alone or in combination with
other treatments. Currently, international guidelines
(EPOS [5]) recommend OCS for severe CRSwNP pa-
tients. A Cochrane review [16] suggests that a short
course of OCS improves quality of life and symptom
control compared to placebo or no treatment for pa-
tients with nasal polyps, although little or no difference
was noted after 3 months. Another review found that as
an adjunct treatment, OCS may result in an improve-
ment in symptom severity and reduction in nasal polyps,
but the quality of evidence was low, and no data were
available to assess the longer-term benefits [17]. To date,
no randomised controlled trials (RCTs) have assessed
the role of OCS for CRSsNP. Prescribing of OCS for
CRS has been evaluated in a number of studies. A UK
survey in 2013 found that 34% of ENT surgeons some-
times or always prescribed OCS as part of maximal
medical therapy for CRS [11]. A Canadian survey in
2016 found that 79% prescribed OCS for CRSwNP,
whilst 23% prescribed them for CRSsNP at least some-
times [18]. The UK Sinonasal Audit in 2000 [12] found
that 14% of CRS patients received OS prior to ESS (18%
of CRSwNP compared to 6% of CRSsNP), suggesting
that OCS use is not routine for all patients prior to ESS.
Health informatics
The health informatics data provided limited informa-
tion about the prescribing of OCS for CRS. The CPRD
only captures primary care prescriptions for CRS, whilst
secondary care prescribing of OCS is only captured if
prescription advice is sent back to the patient’s GP. Data
presented to the panel meeting included combined data
for intranasally administered corticosteroids (INCS) and
OCS. Patients with polyps present and polyps unknown
were both highly likely to receive a steroid prescription
(INCS or OCS) both before and after sinus surgery, but
no conclusions could be drawn for the individual usage
of OCS.
Qualitative findings
GPs reported infrequent use of OCS in primary care,
with some GPs expressing a lack of confidence for use
in CRSwNP. ENT specialists described the use of OCS
for CRSwNP prior to surgery, and for occasional rescue
courses for severe cases. However, concerns were raised
about the potential of a ‘pre-operative blast of steroids’ to
affect surgical outcomes which could consequently affect
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trial results. Likewise, post-operative OCS were de-
scribed as ‘muddying the waters’, resulting in an unclear
picture of the effectiveness of surgery alone. A few pa-
tients had experience of OCS use and described rapid
symptom relief especially after surgery. Whilst there
were some reported concerns about side effects, patients
were generally agreeable to their use if recommended by
their specialist.
Expert panel review
The expert panel agreed that there was insufficient evi-
dence to support the routine use of OCS, either in the
3-month run-up to the MACRO trial or post randomisa-
tion. Nevertheless, it was agreed that a short course of
OCS could be used as a rescue medication during the
trial, whereby usage would be documented and com-
pared between treatment arms.
Care pathways: polyp and non-polyp patients
Current evidence
Care pathways for CRSsNP and CRSwNP are uncertain,
but there are like to be key similarities in patient man-
agement, especially at a the primary care stage. GPs do
not have access to endoscopy or computed tomography
(CT) scanning, and, therefore, distinguishing between
patients based on polyp status is difficult unless polyps
are big enough to be visible at the nostrils. It is likely,
therefore, that primary care management and referral
would be similar for both phenotypes. The Chronic Rhi-
nosinusitis Epidemiology Study found that rates of anti-
biotic use, OCS use, and nasal irrigation were not
significantly different between the two main subgroups
of CRSwNP and CRSsNP patients [19], suggesting simi-
lar treatment pathways. Ultimately, it is possible that a
CRSsNP patient may subsequently develop nasal polyps,
and thus converge any treatment and management path-
ways for CRSsNP and CRSwNP.
Health informatics
From CPRD data, both the ‘polyps present’ and the
‘polyps unknown’ groups showed similar patterns of con-
sultation in primary and secondary care. Prescribing
rates were broadly comparable; however, slightly higher
levels of OCS prescribing were observed in the ‘polyps
present’ group, whilst antibiotic prescribing was slightly
increased when the polyp status was unknown. From the
health economic analysis, where the highest CRS cost
relates to ESS surgery, mean costs per patient were simi-
lar between both groups.
Qualitative research
ENT surgeons and GPs described some differences in
the CRS patient journey for CRSwNP and CRSsNP. Pa-
tients with nasal polyps were described as difficult to
diagnose in primary care due to the lack of diagnostic fa-
cilities, but patients with visible polyps were more likely
to be prescribed medical treatment (steroid drops/OCS)
in primary care and receive an early referral for specialist
opinion. In secondary care, ENT specialists reported that
patients with nasal polyps were more likely to be pre-
scribed OCS and listed earlier for surgery.
For patients without nasal polyps, GPs described them-
selves as confident in making the CRS diagnosis, and
management commonly included a range of INCS sprays.
Onward referral was often not prioritised for non-polyp
patients and patient pressure and lack of treatment re-
sponse were the main drivers to secondary care referral.
In secondary care, patients without nasal polyps were
more likely to receive long-term antibiotics, and patient
preference contributed to the decision for surgery.
Expert panel review
The expert panel considered the options of either con-
ducting separate trials or including both phenotypes in a
single trial. In light of the diagnostic difficulties in pri-
mary care and the possibility that CRS patients without
polyps may subsequently develop them, the expert panel
agreed that two separate studies would be less relevant
to the real-world setting. Including CRSwNP and
CRSsNP patients in a single trial was considered to be
more pragmatic, and likely to provide answers that could
be generalised back to primary care, where polyp status
can be uncertain. It was agreed, however, that trial ana-
lysis should include stratification for polyp status to de-
termine whether outcomes vary by CRS phenotype.
MACRO trial design
Qualitative research
There was a mixed response to the two proposed trial
designs both from clinicians and patients. Some clini-
cians expressed a preference for the single-stage,
three-arm design (Fig. 1) describing it as ‘simple to under-
stand and describe to patients’, potentially easier to recruit
to, and evaluated surgery earlier in the patient pathway.
Likewise, patients liked the simplicity of the design, but
some expressed concerns that surgery was too early in their
treatment journey, without all medical treatment options
being explored first. However, clinicians generally consid-
ered the two-stage, two-comparison design (Fig. 2) to be a
‘more conservative approach’ and more closely aligned to
current practice, but was potentially more complex for pa-
tients to understand. Concerns were also raised about re-
tention of patients for the second randomisation. Patients
generally liked the two-stage, two-comparison design, de-
scribing it as allowing them to try medical treatments first,
with the potential for surgery to be delayed or avoided.
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Expert panel review
The panel agreed that the qualitative work highlighted
barriers and facilitators to both trial designs and debated
the key issues at length. The main issues arising about
the single-stage, three-arm design (Fig. 1) concerned the
use of medical treatment prior to trial entry, and the po-
tential timing of surgery. Some patients were concerned
about the possibility of being randomised to surgery be-
fore all medical treatment options had been explored.
This raised the question about what was considered to
be ‘appropriate medical treatment (AMT)’ before a pa-
tient was deemed a suitable candidate for surgery.
Guidelines suggest that AMT should include a trial of
INCS for at least 8 weeks, with the optional adjunct of
saline irrigation [20]. For CRSsNP patients, a short
course of broad-spectrum antibiotics or low-dose
macrolides is appropriate, and CRSwNP patients may
benefit from a short course of OCS. Health informatics
data identified that most patients receive INCS and a
short course of antibiotics prior in primary care, and,
therefore, were likely to have received AMT prior to
consultation in secondary care where trial recruitment
will take place.
Following intense debate of the key issues, the expert
panel was unable to reach consensus on the trial design
during the panel meeting itself. Further exploratory work
was agreed to help address the key issue surrounding AMT
prior to surgery, including exploring patient views of AMT
prior to surgery, and trial investigator views of patient eligi-
bility for surgery. The following work was carried out:
 Patients who participated in the original qualitative
research (n = 25) were presented with a scenario of
‘being invited to participate in a three-arm trial if
their ENT specialist felt they were eligible for sur-
gery on the basis of already receiving AMT’. In the
sample of patients who responded (n = 18/25), most
agreed that theoretically they would consent to take
part in such a trial. However, seven would not take
part (four patients would prefer to choose their
treatment rather than being randomised, and three
expressed concerns about the risks of early surgery)
 Principal investigators (PIs) for the MACRO trial (n
= 10) were approached to explore their attitudes to
AMT, specifically the treatments that they
considered essential prior to patients being eligible
for surgery (and, hence, the trial). In general, INCS
were described as essential for both CRSwNP and
CRSsNP patients. OCS were considered essential
only for polyp patients. Short-term antibiotics were
often used for both phenotypes but were not gener-
ally considered to be essential. Views on the import-
ance of prior treatment with long-term antibiotics
was varied for both phenotypes. Overall, failed
medical treatment was described as the main criteria
for surgery
These results were presented back to the expert panel
who had the opportunity to consider and review the
additional information and reflect on the panel discus-
sions and opinions of the other panel members. Each
panel member was then asked to vote for their preferred
trial design, by emailing their decision to the programme
manager, describing the reasons for their choice. The re-
sults were collated and a trial design agreed.
The final agreed trial design was a modified, three-arm
design (Fig. 3) where patients would be eligible if the
local PI considered them to be suitable candidates for
further treatment (including surgery). This modified de-
sign addressed the key issues of patient concern about
timing of surgery (patients will have received AMT prior
to being considered eligible for the trial) and AMT
(practice is varied but most patients will have received
antibiotics and INCS in primary care, although macro-
lide treatment is not widely used).
Discussion
Summary
An expert panel review of the best available evidence and
mixed-method data resulted in agreement on key ele-
ments and optimal design for the MACRO trial, consid-
ered most likely to be successful in terms of both
recruitment potential and ability to establish best manage-
ment of patients with CRS. A 12-week course of clarithro-
mycin was agreed as the main non-surgical intervention,
due to its increasing use as a first- and second-line treat-
ment for patients with CRS, and the perceived need to es-
tablish its role in CRS management. The control arm will
receive placebo. Orally administered corticosteroids will
be used as a rescue medication during the trial, rather
than routinely either pre or post trial randomisation, to
limit any potential effects on surgical outcomes and better
reflect current UK prescribing habits. Both CRS pheno-
types will be included in the same trial to ensure the
MACRO trial is both pragmatic and generalisable. A
modified, three-arm design was agreed (Fig. 3). Inclusion
criteria were amended to ensure that the patients re-
cruited into the trial would be eligible for ESS (with a
Sino-nasal outcome test (SNOT-22) score of ≥ 20, evi-
dence of CRS on a recent CT scan), and have received ap-
propriate medical therapy (AMT) as deemed suitable by
their ENT surgeon. The proposed 6-week run-in period
prior to randomisation was removed due to new criteria
for AMT prior to randomisation.
Strengths and limitations
The expert panel process resulted in optimisation of the
final MACRO trial design using a multidisciplinary and
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collaborative approach, ensuring that the agreed trial de-
sign was both relevant and appropriate, and based on
best available evidence.
All members of the panel engaged fully with the expert
panel process and were committed to reaching consen-
sus on all elements of the trial design. Independent
members contributed equally to the discussions and en-
sured that the evidence and data were reviewed in a bal-
anced and impartial way.
There were a number of challenges associated with
conducting this expert panel review. A large amount of
varied and complex data were produced as part of this
work which needed summarising in such a way as to be
relevant and coherent to a range of expert panel mem-
bers. Panel members needed to be sufficiently prepared
to review and debate the evidence and integrate the data,
with the aim of reaching agreement.
The panel consisted of members with different expert-
ise, backgrounds and interests, and often views were
conflicting. It was not possible to reach final agreement
for the overall trial design during the panel meeting it-
self. Panel members needed additional time for consider-
ation of the data presented and reflect on discussions
and opinions from the individual experts and patient
contributors before consensus was reached.
Expert panel process
 The use of an expert panel process is a valid and
valuable method for addressing decision or ‘stop-go’
points in a research programmes
 When decisions are potentially complex, a
multidisciplinary and collaborative approach ensures
that the issues have been discussed and debated in
detail, and outcomes are relevant and considered
 Panel members’ views are often divergent, but it is
important to listen to and consider the individuals’
views and opinions as all are equally important and
valid
 Research teams need to remain open to all possible
outcomes of the panel review, without having
preconceptions or expectations
 When important decisions impact widely on a
research programme, sufficient time should be
allocated for individual reflection, as well as group
discussions. A two-stage process should be consid-
ered if time permits
Conclusion
This expert panel review process has successfully re-
sulted in the production of a modified trial design
deemed most likely to be successful in terms of both re-
cruitment potential and ability to establish best manage-
ment of patients with CRS. The MACRO trial protocol
has received ethical and governance approvals, and the
study opened to recruitment in November 2018.
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